Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease

Umamon Puangthong, Ging-Yuek Robin HsiungDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, CanadaAbstract: Alzheimer’s disease is the most common cause of dementia in older adults. The clinical features include progressive memory decline as w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Umamon Puangthong, Ging-Yuek Robin Hsiung
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://doaj.org/article/1c0efbf441974682b0e6a854784148e5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1c0efbf441974682b0e6a854784148e5
record_format dspace
spelling oai:doaj.org-article:1c0efbf441974682b0e6a854784148e52021-12-02T00:11:25ZCritical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease1176-63281178-2021https://doaj.org/article/1c0efbf441974682b0e6a854784148e52009-10-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-the-long-term-impact-of-memantine-in-treatment-o-a3675https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Umamon Puangthong, Ging-Yuek Robin HsiungDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, CanadaAbstract: Alzheimer’s disease is the most common cause of dementia in older adults. The clinical features include progressive memory decline as well as cognitive deficits with executive dysfunction, language, visual perceptual difficulties, apraxia and agnosia. During the moderate to severe stage of the disease, there is a major decline in memory and function, while neuropsychiatric disturbances often emerge and patients become difficult to manage. These distressing symptoms increase caregiver burden and add to the direct costs of care of the patients. Any improvements in patient function and behavioral symptoms can reduce caregiver burden. Memantine has been available for a number of years in Europe and in North America. In this article, we examine the pharmacological rationale for its use, and the current clinical evidence for its efficacy and long-term effectiveness in the management of cognitive and behavioral symptoms in moderate to severe stages of Alzheimer’s disease.Keywords: memantine, Alzheimer’s disease, dementia Umamon PuangthongGing-Yuek Robin HsiungDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 553-561 (2009)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Umamon Puangthong
Ging-Yuek Robin Hsiung
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
description Umamon Puangthong, Ging-Yuek Robin HsiungDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, CanadaAbstract: Alzheimer’s disease is the most common cause of dementia in older adults. The clinical features include progressive memory decline as well as cognitive deficits with executive dysfunction, language, visual perceptual difficulties, apraxia and agnosia. During the moderate to severe stage of the disease, there is a major decline in memory and function, while neuropsychiatric disturbances often emerge and patients become difficult to manage. These distressing symptoms increase caregiver burden and add to the direct costs of care of the patients. Any improvements in patient function and behavioral symptoms can reduce caregiver burden. Memantine has been available for a number of years in Europe and in North America. In this article, we examine the pharmacological rationale for its use, and the current clinical evidence for its efficacy and long-term effectiveness in the management of cognitive and behavioral symptoms in moderate to severe stages of Alzheimer’s disease.Keywords: memantine, Alzheimer’s disease, dementia
format article
author Umamon Puangthong
Ging-Yuek Robin Hsiung
author_facet Umamon Puangthong
Ging-Yuek Robin Hsiung
author_sort Umamon Puangthong
title Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
title_short Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
title_full Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
title_fullStr Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
title_full_unstemmed Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
title_sort critical appraisal of the long-term impact of memantine in treatment of moderate to severe alzheimer’s disease
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/1c0efbf441974682b0e6a854784148e5
work_keys_str_mv AT umamonpuangthong criticalappraisalofthelongtermimpactofmemantineintreatmentofmoderatetoseverealzheimeramprsquosdisease
AT gingyuekrobinhsiung criticalappraisalofthelongtermimpactofmemantineintreatmentofmoderatetoseverealzheimeramprsquosdisease
_version_ 1718403850102112256